Atlas Trials

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

Clinical trial NCT06029816 · UNKNOWN

Trial details

NCT number
NCT06029816
Sponsor
Convalife (Shanghai) Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2023-11-20
Primary completion
2024-12-30
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.